Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR)Toni K. Choueiri, Neeraj Agarwal, Russell K. Pachynski et al.|The Oncologist|2021Cited by 10
Biomarker modulation in patients treated with TRC105 in combination with anti-VEGF therapy.Yingmiao Liu, Andrew B. Nixon, Zhenhua Yuan et al.|Journal of Clinical Oncology|2017Cited by 1